DC-CIK联合化疗治疗中晚期非小细胞肺癌临床效果评价  

Clinical Effect of DC-CIK Combined with Chemotherapy in Treatment of Patients with Middle-advanced Nonsmall Cell Lung Cancer

作　　者：曲雅静[1] 李广欣[2] 徐丽君[3] 宋宇[3] 穆海玉[4] 

机构地区：[1]武警后勤学院附属医院生物治疗科,天津300162 [2]武警北京总队第三医院肿瘤科,北京100141 [3]武警辽宁总队医院内二科,沈阳110034 [4]武警后勤学院附属医院肿瘤科,天津300162

出　　处：《解放军医药杂志》2015年第11期72-76,88,共6页Medical & Pharmaceutical Journal of Chinese People’s Liberation Army

基　　金：天津市科技计划项目(14ZCZDSY00048);武警后勤学院附属医院种子基金项目(FYM201540)

摘　　要：目的观察树突状细胞(dendritic cell,DC)-细胞因子诱导杀伤细胞(cytokine-induced killers,CIK)联合化疗治疗中晚期非小细胞肺癌(non-small-cell carcinoma,NSCLC)的临床效果。方法选取100例诊断为中晚期NSCLC的患者随机分为观察组与对照组,每组50例。两组均给予紫杉醇+顺铂化疗,观察组在此基础上给予DC-CIK免疫细胞治疗。比较观察两组治疗前后外周血肿瘤标志物、免疫功能指标,近远期临床疗效,及不良反应发生情况。结果两组治疗后外周血细胞角蛋白19血清片段211(CYFRA211)、鳞状细胞癌相关抗原(SCC-Ag)、癌胚抗原(CEA)、癌抗原(CA)125浓度均较治疗前降低(P<0.05);观察组治疗后外周血CYFRA211、SCC-Ag、CEA、CA125浓度低于对照组(P<0.05)。观察组治疗后外周血CD3、CD8、CD56/CD3、CD16/CD3、Ig G、Ig M、Ig A较治疗前有所升高(P<0.05),CD4/CD8降低(P<0.05);对照组外周血CD3、CD8、CD4、CD4/CD8、CD56/CD3、CD16/CD3较治疗前无明显改变(P>0.05),Ig G、Ig M、Ig A较治疗前降低(P<0.05);观察组治疗后外周血CD3、CD8、CD56/CD3、CD16/CD3、Ig G、Ig M、Ig A明显高于对照组(P<0.05),CD4/CD8明显低于对照组(P<0.05)。两组治疗过程中均未出现严重不良反应,治疗后均出现不同程度消化道反应、骨髓抑制,观察组不良反应发生率低于对照组(P<0.05)。结论 DC-CIK联合化疗能提高中晚期NSCLC的临床疗效,且不良反应较小。Objective To investigate the clinical effect of DC （dendric cell, DC）-CIK （cytokine-induced kil- lers） combined with chemotherapy in treatment of patients with middle-advanced non-small cell lung cancer （NSCLC）. Methods A total of 100 patients with middle-advanced non-small cell lung cancer were randomly divided into observa- tion group （n = 50） and control group （n = 50）. All patients were treated with Paclitaxel ＋ Cisplatin chemotherapy, and the observation group was added with DC-CIK treatment of self-immune cells. The tumor markers, immune function inde- xes, the near and long terms of clinical effects and incidence rate of adverse reactions of peripheral blood in the two groups before and after the treatment were observed and compared. Results The concentrations of cytokeratin fragment antiogen 211 （ CYFRA 211 ）, squamous-celled carcinoma-antigen （ SCC-Ag）, carcinoembryonic antigen （CEA） and cancer antigen125 （CA125） in the peripheral blood after the treatment were lower than those before the treatment in the two groups （P 〈0.05） ; the concentrations of CYFRA211, SCC-Ag, CEA and CA125 in the observation group after the treatment were lower than those in the control group （P 〈 0.05）. In the observation group, the levels of CD3, CDS, CD56/CD3, CD16/CD3, immunoglobulin G （IgG）, IgM and IgA in peripheral blood compared with those before the treatment were higher （ P 〈0. 05 ）, while the CD4/CD8 level was lower after the treatment （ P 〈 0. 05 ） ; in control group, there were no significant differences in levels of CD3, CD8, CD4, CD4/CD8, CD56/CD3 and CD16/CD3 in pe- ripheral blood （ P 〉 0. 05 ）, while the levels of IgG, IgM and IgA were significantly lower after the treatment （P 〈 0. 05 ） ;after the treatment, the levels of CD3, CDS, CD56/CD3, CD16/CD3, IgG, IgM and IgA were significantly higher in the observation group than those in the control group （ P 〈 0. 05 ）, while the CD4/CD8 level was significantly lower than that in the c

关 键 词：癌 非小细胞肺 树突状细胞 细胞因子诱导杀伤细胞 治疗结果 免疫 细胞 

分 类 号：R730.26[医药卫生—肿瘤]